Central Nervous System

Acta Pharmaceuticals raises $24m for Alzheimer’s therapies

Acta Pharmaceuticals has secured $24m in seed funding for advancing a drug pipeline focused on early intervention and prevention of Alzheimer’s disease (AD), including the clinical progression of its lead candidate, GSM-779690T.

QCi and INmune Bio partner to study XPro in Alzheimer’s

INmune Bio and Quantum Computing, known as QCi, have agreed to collaborate using quantum computing, AI, and data analytics to explore new indications for XPro (XPro1595), an investigational treatment for Alzheimer’s disease and other medical conditions.

Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy

Japan’s Ministry of Health, Labour and Welfare has approved Viatris’ Wakix (pitolisant) for excessive daytime sleepiness (EDS) related to obstructive sleep apnoea syndrome (OSAS) and for narcolepsy types 1 and 2.

Eli Lilly and QurCan sign genetic medicine deal

Eli Lilly and Company and QurCan Therapeutics have signed an exclusive research and collaboration agreement to develop genetic medicine therapeutics for diseases of the central and peripheral nervous systems.

Médunik and Biocodex sign exclusive agreement for Diacomit in Canada

Médunik Canada has entered an exclusive promotional services agreement with Biocodex for Diacomit, a medication approved in Canada as an add-on therapy for seizures associated with Dravet syndrome.

Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule

China-based Biocytogen Pharmaceuticals has entered a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule.

Teva Pharmaceuticals to acquire BioXcel assets for up to $125m

Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total deal value of $125m.

Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1

Takeda has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Orzeyful (oveporexton) to treat narcolepsy type 1 in adults.

Andelyn Biosciences to develop GM2 gangliosidosis therapy

Andelyn Biosciences is set to develop and manufacture a gene therapy known as AAV9-GM2, for Queen’s University to treat GM2 gangliosidoses, including Tay-Sachs and Sandhoff diseases.